Calibrate vs Found: Choosing the Right GLP-1 Program for Your Goals

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Calibrate and Found are two prominent telehealth platforms offering GLP-1 receptor agonist programs for weight loss and metabolic health. Both use prescription medications (primarily semaglutide or tirzepatide), but they operate under distinctly different clinical and business models that affect cost, provider oversight, medication selection, and ongoing support.

Full head-to-head: PlexusDx vs Found →

Choosing between program structures requires clarity on what matters most to you: provider continuity, medication flexibility, cost predictability, and access to personalized decision tools. This article helps you evaluate both options against clinical evidence and your own health context, including how genetic factors may inform your medication selection process.

Program Structure and Provider Model: Key Clinical Differences

Calibrate emphasizes physician-led care with a dedicated doctor assigned to each patient, who adjusts dosing and monitors progress over time. This continuity model prioritizes long-term clinical oversight and relationship-based medication management, appealing to patients who value consistent provider communication.

Found operates on a broader practitioner network model, connecting patients with available providers (MDs, NPs, PAs) who may rotate or vary. This flexibility can accelerate access but may result in less consistent continuity. Both platforms require medical evaluation before prescribing, though the depth and frequency of oversight varies.

Medication Options, Formulations, and Clinical Availability

Calibrate primarily offers semaglutide injections, with tirzepatide available in select markets. Found provides compounded semaglutide and compounded tirzepatide in injectable form. Medication availability can depend on supply, regional regulations, and individual patient eligibility as determined by the provider.

Found's program is a compounded program — its medications come from partner compounding pharmacies, with medication cost included in the plan price. Calibrate primarily works with branded medications, often through insurance. Compounded formulations, which are manufactured at licensed compounding pharmacies, may offer cost advantages or supply flexibility in certain markets. The choice between branded and compounded options ultimately depends on provider recommendation, availability, and your coverage.

Factor	Calibrate	Found	PlexusDx Compounded
Primary Medications	Semaglutide (injectable), tirzepatide (limited)	Compounded semaglutide and compounded tirzepatide (injectable)	Compounded semaglutide/tirzepatide (injectable/oral)
Formulation Type	Branded pharmaceutical	Compounded (partner compounding pharmacies)	Licensed 503A compounded
Provider Continuity	Assigned physician throughout program	Practitioner network (may vary)	Patient-directed with PlexusDx guidance
Typical Monthly Cost	$200–$350 (per Calibrate's published rates as of July 2026; verify on their site)	Cash: $289/mo compounded semaglutide or $359/mo compounded tirzepatide, medication included; separate insurance track from $99/mo for covered patients (verified July 2026)	$129–$389/mo month-to-month, by protocol

Pricing, Insurance Integration, and Transparency in Costs

Calibrate typically charges between $200–$350 monthly, with prices varying by state. The program often works with insurance and may reduce out-of-pocket costs for eligible patients. Pricing includes provider access, regular check-ins, and prescription management through their pharmacy network.

Found's cash compounded-semaglutide program is $289/month (prepaid plans run $249/mo for 3 months, $219/mo for 6 months, or $169/mo for 12 months), billed every four weeks — 13 charges a year on the monthly plan — with medication included and no separate membership fee. Compounded tirzepatide is $359/month cash. Found also runs a separate insurance track: covered patients may pay from $99/month, with a $199/month floor — an insurance figure that should never be read as a cash price. Final cost depends on which track you qualify for, so confirm cash versus insurance pricing at enrollment.

Clinical Considerations and Who Should Evaluate Each Option

Both Calibrate and Found conduct medical screening to assess candidacy, including BMI thresholds, cardiovascular history, and medication interactions. Patients with Type 2 diabetes, cardiovascular disease, or thyroid cancer history require careful provider evaluation. Neither platform provides care for patients with active pancreatitis or medullary thyroid cancer history.

Your choice may depend on whether you prefer consistent physician oversight (Calibrate's model) or broader practitioner access (Found's approach), and whether you prioritize branded medications (Calibrate's primary model) or compounded formulations (the model Found and PlexusDx use), which can carry cost advantages. A qualifying healthcare provider should evaluate your specific health profile, genetics, and treatment goals before initiating any GLP-1 program.

How PlexusDx Supports a More Personalized Approach

PlexusDx compounded GLP-1 medications offer a clinically distinct alternative to both Calibrate and Found, using licensed 503A pharmacy formulations that may provide cost savings and supply flexibility. Compounded semaglutide and tirzepatide are not identical to branded versions, and your provider should discuss formulation differences, potency, and shelf-life considerations. This approach may help provide context for patients seeking lower entry-point pricing or more flexible dosing options alongside their provider's clinical guidance.

The PlexusDx Precision Peptide Genetic Test examines predispositions in key GLP-1 receptor and metabolic pathways (including GIPR rs1800437, FTO rs9939609 variants). These insights may help inform conversations with your provider about which GLP-1 medication class or dosing approach aligns with your genetic background. The test does not predict exact medication response or guarantee outcomes, but can support a more informed clinical dialogue.

Whether you choose Calibrate, Found, or explore compounded GLP-1 options through PlexusDx, integrating genetic and biomarker context into your decision process may enhance personalization. A qualified healthcare provider should interpret any genetic findings alongside your medical history, BMI, comorbidities, and treatment goals to recommend the most appropriate program and medication.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Calibrate or Found better for weight loss outcomes?

Both programs show clinical benefit for weight loss when combined with lifestyle changes; outcomes depend more on adherence and individual response than platform choice. Provider continuity (Calibrate) may support sustained engagement, while Found's access model may suit patients prioritizing quick enrollment.

Do Calibrate and Found accept insurance?

Calibrate often works with insurance, and Found runs a separate insurance track (from $99/month for covered patients, with a $199/month floor). Paying cash, Calibrate generally runs $200–$350 monthly, while Found's compounded-semaglutide program is $289/month with medication included. Coverage depends on BMI, comorbidities, and your plan's GLP-1 formulary placement.

What's the difference between branded semaglutide and compounded semaglutide?

Branded semaglutide (Ozempic/Wegovy) is manufactured by Novo Nordisk. Compounded semaglutide is formulated at licensed 503A pharmacies. Both contain the same active ingredient but differ in manufacturing, stability, and cost. Your provider should discuss formulation options and any differences in potency or storage.

Can I switch between programs if my current provider isn't working?

Yes. Most GLP-1 programs allow you to transition to another provider or platform. Coordinate with your previous prescriber to request medical records. There's no lock-in period, though continuing your current medication dose may ease the transition.

How could genetic testing help me choose between these programs?

PlexusDx Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor and metabolic pathways. These insights may support a more informed conversation with your provider about which medication class or program aligns with your genetic profile, though genetics does not predict exact medication response.

Related Reading

• Found Glp 1
• Found Semaglutide
• Found Weight Loss
• Wegovy Medication

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.